Swiss Semiconductors Stock News

C4 Therapeutics recently announced a collaboration with Roche to develop degrader-antibody conjugates for oncology, while Roche also launched its cobas MPX-E blood screening assay in CE-mark accepting countries, consolidating HIV and hepatitis virus detection into a single high-throughput test. Together, these moves underline Roche’s push to pair next-generation cancer modalities with advanced diagnostics that can improve laboratory efficiency and transfusion safety worldwide. We’ll now...

VAT Group (SWX:VACN) updated investors after cutting first quarter 2026 sales guidance to around CHF 215 million following supply chain disruptions, while reiterating that full year 2026 metrics are expected to be higher than 2025 levels. See our latest analysis for VAT Group. Despite the revised first quarter guidance, VAT Group’s recent trading has stayed firm, with a 7 day share price return of 9.15% and a 90 day share price return of 20.40%. The 1 year total shareholder return of 95.41%...

If you are wondering whether Alcon's current share price reflects its true worth, the recent performance offers some clear signals to unpack. The stock last closed at $61.00, with a 1.1% gain over the past week, a 3.3% decline over 30 days, and returns of 4.0% decline year to date and 15.5% decline over the past year. These moves sit against a backdrop where investors have been reassessing medical equipment names and updating their expectations for companies like Alcon. Sector sentiment...

Logitech International stock: understanding recent performance Logitech International (SWX:LOGN) has drawn investor attention after a recent pullback, with the share price showing a 3.4% decline over the past day and a 1.7% move lower over the past week. See our latest analysis for Logitech International. That short term weakness sits against a mixed backdrop, with the 90 day share price return of 6.8% decline and a year to date share price return of 9.3% decline contrasting with a 1 year...

Novartis (SWX:NOVN) is back in focus after releasing final two year Phase III data for Fabhalta in IgA nephropathy, which showed clinically meaningful kidney outcomes versus placebo and supports an ongoing FDA priority review. See our latest analysis for Novartis. The Fabhalta readout appears to be feeding into sentiment, with the share price at CHF122.18 and a 90 day share price return of 7.14%. The 1 year total shareholder return of 48.62% contrasts with a more modest 12.61% year to date...

R&S Group Holding (SWX:RSGN) has reported its FY 2025 figures with first half revenue of CHF 206.3 million and basic EPS of CHF 0.77, set against trailing twelve month revenue of CHF 417.7 million and EPS of CHF 1.56 that reflect a 41% earnings increase over the last year. The company has seen revenue move from CHF 172.7 million in the second half of FY 2024 to CHF 206.3 million in the first half of FY 2025, with EPS shifting from CHF 0.86 to CHF 0.77 in those respective periods. This leaves...

Jungfraubahn Holding (SWX:JFN) has just released full year 2025 results together with a higher annual dividend, giving investors fresh information on earnings, cash returns and how the business exited last year. See our latest analysis for Jungfraubahn Holding. The share price reaction has been positive in the short term, with a 5.1% 1 day share price return and 5.7% 7 day share price return. The 1 year total shareholder return of 69.1% reflects much stronger gains over a longer period. If...

SoftwareOne Holding AG has released its 2025 results, reporting sales of CHF 1,243.4 million and net income of CHF 0.9 million, while proposing a reduced CHF 0.15 per share dividend and setting 2026 guidance for mid-single digit constant-currency revenue growth and a 30%–50% adjusted profit pay-out ratio. Alongside these figures, the company announced a leadership change in human resources, with long-time insider Nina Janorschke stepping in as Chief Human Resources Officer, which may help...

Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be...

Readers hoping to buy Schweiter Technologies AG ( VTX:SWTQ ) for its dividend will need to make their move shortly, as...

Lonza Group AG ( VTX:LONN ) just reported healthy earnings but the stock price didn't move much. Our analysis suggests...

Readers hoping to buy Julius Bär Gruppe AG ( VTX:BAER ) for its dividend will need to make their move shortly, as the...

Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see Emmi AG...

Two veteran UBS Group advisors overseeing about $2.4b in client assets have left the firm’s U.S. brokerage unit. They have launched Evertern Wealth, an independent advisory firm focused on high net worth clients. The departures highlight ongoing movement of experienced advisers from large banks toward independent platforms. For investors following UBS Group (SWX:UBSG), this shift comes as the stock trades around CHF32.4, with a 7 day return of 2.7% and a 30 day return of 9.4%. Over longer...

Roche’s new cobas MPX-E assay and why it matters for shareholders Roche Holding (SWX:ROG) has launched its cobas MPX-E multiplex assay in CE mark countries, offering simultaneous screening for HIV, HCV, HBV and HEV on existing cobas x800 systems to support higher throughput donor testing. See our latest analysis for Roche Holding. Roche’s share price has softened recently, with a 30 day share price return of 10.47% and a year to date share price return of a 0.98% decline, even though the 1...

As European markets experience a positive shift, with the STOXX Europe 600 Index gaining 3.92% amid hopes for a shorter-lived Middle East conflict, investors are keenly observing how energy market volatility and inflation trends might impact dividend stocks. In this context, selecting robust dividend stocks involves considering companies with strong financial health and stable cash flows that can weather economic fluctuations while continuing to provide reliable income streams.

Dividend announcement puts yield in focus for BCGE Banque Cantonale de Genève (SWX:BCGE) has announced an annual dividend of CHF 0.5250 per share, with the stock trading ex dividend on 5 May 2026 and payment scheduled for 7 May 2026. See our latest analysis for Banque Cantonale de Genève. The dividend news follows a strong run in the shares, with a 30 day share price return of 12.38% and a 90 day share price return of 40.48%. The 1 year total shareholder return of 48.30% highlights how...

If you are wondering whether UBS Group's current share price reflects its true worth, you are not alone. That is exactly what this article is here to unpack. UBS Group closed at CHF31.16 recently, with returns of 1.4% over the past 7 days, 4.4% over the past 30 days, a year to date return of negative 18.4%, 39.6% over 1 year, 79.1% over 3 years and 141.6% over 5 years, hinting at shifting expectations around both opportunity and risk. Recent coverage has focused on UBS Group's ongoing...

Wondering if Logitech International at around $73.32 is offering genuine value or just riding sentiment? This article breaks down what the current share price might be implying about the business. The stock has returned 1.3% over the last 7 days and 4.6% over the last 30 days, set against a year to date return of a 7.8% decline and a 25.7% return over 1 year, with a 49.7% return over 3 years and a 21.4% decline over 5 years. Recent coverage has focused on Logitech International as an...

Investors were underwhelmed by the solid earnings posted by SoftwareOne Holding AG ( VTX:SWON ) recently. Our analysis...

If you are wondering whether Novartis at around CHF123 per share still offers value, the key is to look past the headline price and focus on what you are actually getting for each franc invested. The stock has returned 1.9% over the last week, is roughly flat over 30 days, and has delivered 13.5% year to date alongside 43.2% over 1 year, 65.7% over 3 years, and 96.0% over 5 years. This naturally raises questions about how much of the story is already reflected in the price. Recent attention...

Why Nestlé (SWX:NESN) is on investors’ radar today Nestlé (SWX:NESN) continues to attract attention as investors reassess large consumer staples groups, with the share price around CHF 78.37 and recent returns mixed across the past month and past 3 months. See our latest analysis for Nestlé. While the share price is around CHF78.37 with a 90 day share price return of 2.90%, the 1 year total shareholder return of 2.91% decline and 3 year total shareholder return of 24.37% decline point to...

Roche Holding (SWX:ROP) has attracted fresh attention after announcing the cobas MPX-E assay, a CE-marked in vitro test that screens for HIV and multiple hepatitis viruses in a single high-throughput run. See our latest analysis for Roche Holding. Roche’s recent diagnostics launches and R&D investment news arrive while the share price sits at CHF318.0, with a 30 day share price return of a 6.8% decline but a 1 year total shareholder return of 33.17% that points to stronger long term...

As global markets navigate the complexities of Middle East tensions and energy market volatility, major indices like the Nasdaq Composite have shown resilience with notable gains, reflecting a cautiously optimistic sentiment amid geopolitical uncertainties. In such an environment, growth companies with significant insider ownership often attract attention due to their potential for alignment between management and shareholder interests, which can be particularly appealing when navigating...